Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,091 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach.
Nyberg F, Askling J, Berglind N, Franzén S, Ho M, Holmqvist M, Horne L, Lampl K, Michaud K, Pappas DA, Reed G, Symmons D, Tanaka E, Tran TN, Verstappen SM, Wesby-van Swaay E, Yamanaka H, Greenberg JD. Nyberg F, et al. Among authors: ho m. Pharmacoepidemiol Drug Saf. 2015 Nov;24(11):1121-32. doi: 10.1002/pds.3854. Epub 2015 Aug 25. Pharmacoepidemiol Drug Saf. 2015. PMID: 26303866
Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease.
Michaud K, Berglind N, Franzén S, Frisell T, Garwood C, Greenberg JD, Ho M, Holmqvist M, Horne L, Inoue E, Nyberg F, Pappas DA, Reed G, Symmons D, Tanaka E, Tran TN, Verstappen SM, Wesby-van Swaay E, Yamanaka H, Askling J. Michaud K, et al. Among authors: ho m. Ann Rheum Dis. 2016 Oct;75(10):1797-805. doi: 10.1136/annrheumdis-2015-208698. Epub 2016 Feb 8. Ann Rheum Dis. 2016. PMID: 26857699
Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme.
Yamanaka H, Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Ho M, Holmqvist M, Novelli Horne L, Inoue E, Michaud K, Pappas DA, Reed G, Symmons D, Tanaka E, Tran TN, Verstappen SMM, Wesby-van Swaay E, Nyberg F. Yamanaka H, et al. Among authors: ho m. RMD Open. 2017 Oct 10;3(2):e000498. doi: 10.1136/rmdopen-2017-000498. eCollection 2017. RMD Open. 2017. PMID: 29081988 Free PMC article.
Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries.
Verstappen SM, Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Holmqvist M, Horne L, Lampl K, Michaud K, Nyberg F, Pappas DA, Reed G, Symmons DP, Tanaka E, Tran TN, Yamanaka H, Ho M. Verstappen SM, et al. Among authors: ho m. Arthritis Care Res (Hoboken). 2015 Dec;67(12):1637-45. doi: 10.1002/acr.22661. Arthritis Care Res (Hoboken). 2015. PMID: 26201948 Free article.
How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries.
Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Ho M, Holmqvist M, Horne L, Inoue E, Michaud K, Nyberg F, Pappas DA, Reed G, Tanaka E, Tran TN, Verstappen SM, Yamanaka H, Wesby-van Swaay E, Symmons D. Askling J, et al. Among authors: ho m. Ann Rheum Dis. 2016 Oct;75(10):1789-96. doi: 10.1136/annrheumdis-2015-208105. Epub 2015 Nov 30. Ann Rheum Dis. 2016. PMID: 26621482
Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study.
Pappas DA, Nyberg F, Kremer JM, Lampl K, Reed GW, Horne L, Ho M, Onofrei A, Malaviya AN, Rillo OL, Radominski SC, Gal J, Gibofsky A, Popkova TV, Laurindo L, Kerzberg EM, Zahora R, Pons-Estel BA, Curtis JR, Furst DE, Greenberg JD. Pappas DA, et al. Among authors: ho m. Clin Rheumatol. 2018 Sep;37(9):2331-2340. doi: 10.1007/s10067-018-4113-3. Epub 2018 Apr 25. Clin Rheumatol. 2018. PMID: 29696436
Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Weinblatt ME, Genovese MC, Ho M, Hollis S, Rosiak-Jedrychowicz K, Kavanaugh A, Millson DS, Leon G, Wang M, van der Heijde D. Weinblatt ME, et al. Among authors: ho m. Arthritis Rheumatol. 2014 Dec;66(12):3255-64. doi: 10.1002/art.38851. Arthritis Rheumatol. 2014. PMID: 25223724 Clinical Trial.
4,091 results